AMINAZINE 25MG PILLS

Latin name

Aminazine

Release form

Dragee

Packaging 10 pieces.

Pharmacology

Aminazine is an antipsychotic (neuroleptic) from the group of phenothiazine derivatives. It has a pronounced antipsychotic, sedative, antiemetic effect. Weakens or completely eliminates delusions and hallucinations, suppresses psychomotor agitation, reduces affective reactions, anxiety, anxiety, lowers physical activity.

The mechanism of antipsychotic action is associated with the blockade of postsynaptic dopaminergic receptors in the mesolimbic structures of the brain. It also has a blocking effect on α-adrenoreceptors and suppresses the release of pituitary and hypothalamic hormones. However, the blockade of dopamine receptors increases the secretion of prolactin by the pituitary.

The central antiemetic effect is due to the inhibition or blockade of dopamine D2 receptors in the chemoreceptor trigger zone of the cerebellum, and the peripheral blockade of the vagus nerve in the gastrointestinal tract. The antiemetic effect is enhanced, apparently due to anticholinergic, sedative and antihistamine properties. Sedative effect is due, apparently, alpha-blocking activity. It has a moderate or weak extrapyramidal effect.

Indications

• chronic paranoid and hallucinatory-paranoid states;
• psychomotor agitation in patients with schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes);
• alcoholic psychosis, manic arousal in patients with manic-depressive psychosis;
• mental disorders in patients with epilepsy;
• agitated depression in patients with presenile, manic-depressive psychosis;
• neurotic diseases accompanied by increased muscle tone;
• pain, incl. causalgia (in combination with analgesics);
• persistent sleep disturbance (in combination with sleeping pills and tranquilizers);
• Meniere's disease;
• vomiting of pregnant women;
• treatment and prevention of vomiting during treatment with anticancer agents and during radiation therapy;
• pruritic dermatosis;
• as part of "lytic mixtures" in anesthesiology

Contraindications

• Hypersensitivity;
• abnormal liver and / or kidney function;
• dysfunction of the blood;
• progressive systemic diseases of the brain and spinal cord;
• myxedema;
• decompensated heart disease;
• thromboembolic disease;
• late stage bronchiectasis;
• coma;
• brain injury

With care, under careful control, it is necessary to prescribe a drug for gallstone and urolithiasis, acute pyelitis, rheumatism, rheumatic carditis.

Do not recommend Aminazine for gastric ulcer and duodenal ulcer.With long-term use of the drug, it is necessary to monitor the picture of peripheral blood, prothrombin index, liver and kidney function, neurological examinations and consultation of an ophthalmologist. In experimental studies established embryotoxic effect of the drug.

Pregnanacy and breastfeeding

If necessary, the use of chlorpromazine during pregnancy should limit the treatment time, and at the end of pregnancy, if possible, reduce the dose. It should be borne in mind that chlorpromazine prolongs labor.

If necessary, use during lactation breastfeeding should be discontinued.

Special notes

With particular caution, phenothiazines are used in patients with pathological changes in the blood picture, in disorders of liver function, alcohol intoxication, Reye's syndrome, as well as in breast cancer, cardiovascular diseases, susceptibility to the development of glaucoma, Parkinson's disease, gastric ulcer and duodenal ulcer., urinary retention, chronic diseases of the respiratory system (especially in children), epileptic seizures.

Phenothiazines should be used with caution in elderly patients (increased risk of excessive sedative and hypotensive action), in exhausted and weakened patients.

In the event of hyperthermia, which is one of the symptoms of ZNS, chlorpromazine should be immediately canceled.

In children, especially with acute diseases, the use of phenothiazines is more likely to develop extrapyramidal symptoms.

During the period of treatment to prevent the use of alcohol.

Influence on ability to drive motor transport and control mechanisms

It should be used with caution in patients engaged in potentially hazardous activities that require a high rate of psychomotor reactions.

Active ingredient

1 pill contains:
active substance: chlorpromazine hydrochloride 25 mg

Dosage and administration

The dosage regimen is set individually. When ingested for adults, a single dose is 10-100 mg, daily dose - 25-600 mg; for children aged 1-5 years - 500 mcg / kg every 4-6 hours, for children older than 5 years, you can apply 1 / 3-1 / 2 adult doses.

The frequency of oral administration depends on the indications and the clinical situation.

The maximum single dose: for adults when administered orally - 300 mg.

The maximum daily intake: for adults when taken orally - 1.5 g; for children under the age of 5 years (body weight up to 23 kg) when taken orally, for children over the age of 5 years (body weight more than 23 kg) when taken orally.

Adverse effects

From the side of the central nervous system: possible akathisia, blurred vision; rarely - dystonic extrapyramidal reactions, parkinson syndrome, tardive dyskinesia, disturbances of thermoregulation, MNS; in isolated cases - seizures.

Cardiovascular: possible arterial hypotension (especially with a / in the introduction), tachycardia.

On the part of the digestive system: dyspeptic phenomena are possible (by ingestion); rarely - cholestatic jaundice.

On the part of the blood system: rarely - leukopenia, agranulocytosis.

From the urinary system: rarely - difficulty urinating.

On the part of the endocrine system: menstrual disorders, impotence, gynecomastia, weight gain.

Allergic reactions: skin rash, itching; rarely - exfoliative dermatitis, erythema multiforme.

Dermatological reactions: rarely - skin pigmentation, photosensitivity.

On the part of the organ of vision: with long-term use in high doses, chlorpromazine may be deposited in the anterior structures of the eye (cornea and lens), which can accelerate the processes of normal aging of the lens.

Drug interactions

With the simultaneous use of drugs that have a depressant effect on the central nervous system, ethanol, ethanol-containing drugs may increase the inhibitory effect on the central nervous system, as well as respiratory depression.
With the simultaneous use of tricyclic antidepressants, maprotiline, MAO inhibitors may increase the risk of developing NNS.
At simultaneous use with anticonvulsants it is possible to decrease the threshold of convulsive readiness; with agents for the treatment of hyperthyroidism - an increased risk of agranulocytosis; with drugs that cause extrapyramidal reactions - an increase in the frequency and severity of extrapyramidal disorders is possible; with drugs that cause arterial hypotension - perhaps an additive effect on blood pressure,which leads to severe arterial hypotension, increased orthostatic hypotension.

When used simultaneously with amphetamines, antagonistic interaction is possible; with anticholinergics - increased anticholinergic action; with anticholinesterase agents - muscle weakness, worsening of the course of myasthenia.

With simultaneous use with antacids containing aluminum and Magnesium hydroxide, the concentration of chlorpromazine in the blood plasma decreases due to a violation of its absorption from the gastrointestinal tract.

With simultaneous use of barbiturates increase the metabolism of chlorpromazine, inducing microsomal liver enzymes and thereby reducing its concentration in the blood plasma.

With the simultaneous use of hormonal contraceptives for oral administration described a case of increasing the concentration of chlorpromazine in the blood plasma.

With simultaneous use with epinephrine, a "perversion" of the pressor action of epinephrine is possible, as a result, only β-adrenoreceptors are stimulated and severe hypotension and tachycardia occur.

With simultaneous use with Amitriptyline increases the risk of tardive dyskinesia. Cases of the development of paralytic ileus are described.

With simultaneous use, chlorpromazine may reduce or even completely inhibit the antihypertensive effect of guanethidine, although some patients may show the hypotensive effect of chlorpromazine.

With simultaneous use with diazoxide, severe hyperglycemia is possible; with doxepin - potentiation of hyperpyrexia; with zolpidem - significantly increased sedative effect; with zopiclone - may increase the sedative effect; with imipramine - the concentration of imipramine in the blood plasma increases.

With simultaneous use of chlorpromazine inhibits the effects of levodopa due to the blockade of dopamine receptors in the central nervous system. Extrapyramidal symptoms may increase.

With simultaneous use of lithium carbonate, pronounced extrapyramidal symptoms, neurotoxic effects are possible; with morphine - the development of myoclonus is possible.

With simultaneous use of nortriptyline in patients with schizophrenia, a worsening of the clinical condition is possible, despite an elevated level of chlorpromazine in the blood plasma. Cases of the development of paralytic ileus are described.

With simultaneous use with piperazine, a case of seizures has been described; with propranolol - an increase in plasma concentrations of propranolol and chlorpromazine; with trazodone - hypotension is possible; with trihexyphenidyl - there are reports of the development of paralytic ileus; with trifluoperazine - cases of severe hyperpyrexia are described; with phenytoin - it is possible to increase or decrease the concentration of phenytoin in the blood plasma.

Manifested by neuroleptic syndrome, persistent hypotension, hypothermia, coma, and later - toxic hepatitis.

Store in a dry, dark place and out of reach of children, at a temperature not exceeding 25 ° C.